A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 19 May 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Navitoclax (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome; Waldenstrom's macroglobulinaemia
Focus Adverse reactions; Biomarker; Therapeutic Use
Sponsors Abbott Laboratories; AbbVie

01 Apr 2021 Results (n=26) of phase 2a part assessing safety and efficacy navitoclax, published in the Leukemia and Lymphoma
10 Nov 2016 Status changed from active, no longer recruiting to completed.
10 Nov 2016 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com